

Zydus Lifesciences launches ANVIMO for transplant patients

05 March 2025 | News

For prevention of Cytomegalovirus infection for haematopoietic stem cell transplant and kidney transplant patients



Ahmedabad-based Zydus, a leading, discovery-based, global lifesciences company, has announced the launch of ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will be available in dosages of 240 mg and 480 mg.

CMV infection remains one of the most serious complications in transplant patients, often leading to graft failure, decreased survival and prolonged hospital stays. Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes.

Transplantation is a life-saving but financially burdensome procedure in India. The high cost of post-transplant care, particularly CMV prophylaxis, adds to the burden. Until now, innovator Letermovir 240 mg was imported at Rs 5+ lakh per month, severely limiting access. With the launch of ANVIMO, Zydus has significantly reduced the cost by 91% of the innovator price, making treatment of CMV prophylaxis significantly more affordable for Indian patients. ANVIMO has established bioequivalence with the reference drug, ensuring quality at a fraction of the cost.

With ANVIMO, Zydus Lifesciences is transforming CMV prophylaxis in India, ensuring that more transplant patients receive timely, effective, and affordable care, ultimately improving survival rates and quality of life.